// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

How can the management of major obstetric haemorrhage be improved? A single‐centre five‐year audit in a high‐risk obstetric unit in London

Netto M - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Major obstetric haemorrhage

N/A

Second trimester 12‐day delayed twin delivery interval with a positive neonatal outcome: a case report and overview of current practice

Moran O - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Chorioamnionitis

N/A

Virtual reality as a distraction therapy in obstetrics and gynaecology

Harper AM - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Sitting on a goldmine. A guide to using routinely collected NHS data to answer research questions – the POOL study example

Sanders J - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Supporting maternal choice and theatre birth experience: a prospective audit of skin‐to‐skin contact during caesarean

Tiong B - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Getting the right information to the right people at the right time: a quality improvement project to improve obstetric daily handover in NHS Fife

Simpson L - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Intrapartum and postpartum outcomes for teenage pregnancy

Wilson-Theaker W - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Evaluation of induction of labour and large for gestational age pregnancies at Musgrove Park Hospital

Capay E - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Shoulder dystocia

N/A

Improving intrapartum fetal monitoring interpretation and reducing harm at Sherwood Forest Hospitals NHS Foundation Trust

Al-Samarrai S - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of the Cook cervical ripening balloon and prostaglandin E2 gel for induction of labour in women who have had a previous caesarean section

Southward J - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dinoprostone

#hellomyroleis– ‘A multidisciplinary quality improvement project using role distinguished colour coded lanyards to improve patient experience and safety in Maternity’

Goodyear G - British Maternal & Fetal Medicine Society (BMFMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The impact of diet and society on the evolution and current health of the oral cavity and associated structures

Kavita Ravi-Shankar - World Congress on Dentistry and Oral Health , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Study of wisdom teeth referrals into Birmingham Dental Hospital, UK

Jinesh Shailesh Thakrar - World Congress on Dentistry and Oral Health , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The FLAMSA‐Bu conditioning regimen does not improve outcome in patients allografted for high‐risk acute myeloid leukaemia and myelodysplasia irrespective of pretransplant MRD: results of the UK NCRI FIGARO trial

C. Craddock - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cytarabine liposomal

First analysis of the UKALL14 phase 3 randomised trial to determine if the addition of rituximab to standard induction chemotherapy improves EFS in adults with precursor B‐ALL (CRUK/09/006)

D. I. Marks - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

CIP2A: its validation as a predictive biomarker of subsequent progression to blast crisis in CML

C. Lucas - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

dasatinib

Decision tree application (DTA) to support accurate diagnosis of myeloid malignancies

T. Coats - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry

S. Todd - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Dexamethasone

Fostamatinib as second‐line therapy and in earlier stage disease in patients with immune thrombocytopenia

N. Cooper - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Immune thrombocytopenia

Fostamatinib

A phase 2 open‐label study of danicopan (ACH‐0144471) in patients with paroxysmal nocturnal haemoglobinuria who have an inadequate response to eculizumab monotherapy

A. Kulasekararaj - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Copyright © 2026. QuantiNova All rights reserved